The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Status:
Completed
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ
clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19
patients.